- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Draxis to buy Ivax manufacturing site
Draxis Health has entered into a memorandum of agreement with Ivax to acquire that firm's Kirkland, Quebec, pharmaceutical manufacturing facility. The 238,000-sq-ft facility will serve as the permanent site for Draxis Health's radiopharmaceutical
Draxis Health has entered into a memorandum of agreement with Ivax to acquire that firm's Kirkland, Quebec, pharmaceutical manufacturing facility. The 238,000-sq-ft facility will serve as the permanent site for Draxis Health's radiopharmaceutical subsidiary, Draximage, which announced plans for growth in February (SCAN 2/18/98).
The facility, whose sterile manufacturing department produces prescription pharmaceuticals for the U.S. and Canadian marketplace, is also expected to assume manufacturing responsibilities for the Mississauga, Ontario-based company's SpectroPharm Dermatology product line, as well as Anipryl, the firm's veterinary drug that was recently licensed to Pfizer Animal Health. The acquisition of the facility was expected to close in late March.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
